PETACH TIKVA, Israel,
Sept. 13, 2016 /PRNewswire/
-- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a
biotechnology company with a pipeline of proprietary small molecule
drugs being developed to treat inflammatory diseases, cancer and
sexual dysfunction, today announced that it has received a Notice
of Allowance from the European Patent Office indicating the patent
titled, "Pharmaceutical Composition Comprising A3 Adenosine
Receptor Agonist (IB-MECA/CF-101) for Treatment of Psoriasis" will
be granted. This key patent addresses Can-Fite's lead drug
candidate Piclidenoson (CF101), an Adenosine Receptor Agonist
(A3AR), in the treatment of psoriasis.
Piclidenoson will be evaluated in an upcoming Phase III trial in
Europe in which it will be
compared to apremilast (Otezla®), a recently approved oral drug
from Celgene. Can-Fite submitted its Phase III clinical trial
protocol for Piclidenoson in the treatment of moderate-to-severe
psoriasis to the European Medicines Agency (EMA) in the first half
of 2016.
"This important psoriasis patent comes at an opportune time, as
we are heading into a Phase III trial in Europe. A similar patent was granted to
Can-Fite in the U.S. last year. We believe our robust global IP
portfolio supports our market position, as we look ahead towards
potential commercialization and out-licensing deals in our advanced
stage indications," stated Can-Fite CEO Dr. Pnina Fishman.
An estimated 3.7 million Europeans have psoriasis, 2.4 million
of whom are living with moderate to severe disease according to the
European Federation of Pharmaceutical Industries and Associations.
Globally, the psoriasis market which was estimated at $6.6 billion in 2014, is projected to double to
over $13.3 billion by 2024, according
to Global Data.
About Piclidenoson (CF101)
Piclidenoson is a novel, first-in-class, A3 adenosine receptor
agonist (A3AR) small molecule, orally bioavailable drug with a
favorable therapeutic index demonstrated in Phase II clinical
studies. Piclidenoson is currently under development for the
treatment of autoimmune inflammatory diseases including rheumatoid
arthritis (completed Phase II) and psoriasis (completed Phase
II/III).
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an
advanced clinical stage drug development Company with a platform
technology that is designed to address multi-billion dollar markets
in the treatment of cancer, inflammatory disease and sexual
dysfunction. The Company's lead drug candidate, Piclidenoson, is
scheduled to enter Phase III trials in 2016 for two indications,
rheumatoid arthritis and psoriasis. The rheumatoid arthritis Phase
III protocol has recently been agreed with the European Medicines
Agency. Can-Fite's liver cancer drug CF102 is in Phase II trials
for patients with liver cancer and is slated to enter Phase II for
the treatment of non-alcoholic steatohepatitis (NASH). CF102 has
been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second
line treatment for hepatocellular carcinoma by the U.S. Food and
Drug Administration. CF102 has also shown proof of concept to
potentially treat other cancers including colon, prostate, and
melanoma. CF602, the Company's third drug candidate, has shown
efficacy in the treatment of erectile dysfunction in preclinical
studies and is being prepared for an IND submission to the FDA and
a Phase I trial. These drugs have an excellent safety profile
with experience in over 1,000 patients in clinical studies to date.
For more information please visit: www.can-fite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about
Can-Fite's expectations, beliefs or intentions regarding, among
other things, its product development efforts, business, financial
condition, results of operations, strategies or prospects. In
addition, from time to time, Can-Fite or its representatives have
made or may make forward-looking statements, orally or in writing.
Forward-looking statements can be identified by the use of
forward-looking words such as "believe," "expect," "intend,"
"plan," "may," "should" or "anticipate" or their negatives or other
variations of these words or other comparable words or by the fact
that these statements do not relate strictly to historical or
current matters. These forward-looking statements may be included
in, but are not limited to, various filings made by Can-Fite with
the U.S. Securities and Exchange Commission, press releases or oral
statements made by or with the approval of one of Can-Fite's
authorized executive officers. Forward-looking statements relate to
anticipated or expected events, activities, trends or results as of
the date they are made. Because forward-looking statements relate
to matters that have not yet occurred, these statements are
inherently subject to risks and uncertainties that could cause
Can-Fite's actual results to differ materially from any future
results expressed or implied by the forward-looking statements.
Many factors could cause Can-Fite's actual activities or results to
differ materially from the activities and results anticipated in
such forward-looking statements, including, but not limited to, the
factors summarized in Can-Fite's filings with the SEC and in its
periodic filings with the TASE. In addition, Can-Fite
operates in an industry sector where securities values are highly
volatile and may be influenced by economic and other factors beyond
its control. Can-Fite does not undertake any obligation to
publicly update these forward-looking statements, whether as a
result of new information, future events or otherwise.
Contact
Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/can-fite-receives-notice-of-allowance-for-psoriasis-patent-in-europe-ahead-of-phase-iii-trial-300326740.html
SOURCE Can-Fite BioPharma Ltd.